In one paragraphArticle in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Fanni ŐszDepartment of Biological Anthropology, Eötvös Lorand University, H-1117 Budapest, Hungary.
Mahmood AkbarAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India.
Balázs Zoltán ZsidóPharmacoinformatics Unit, Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, H-7624 Pécs, Hungary.
Csaba HetényiPharmacoinformatics Unit, Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, H-7624 Pécs, Hungary.ORCID 0000-0002-8013-971X Tamás I OrbánGene Regulation Research Group, Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, H-1117 Budapest, Hungary.ORCID 0000-0002-3424-3428 Ábel FóthiGene Regulation Research Group, Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences, H-1117 Budapest, Hungary.ORCID 0000-0001-7398-9700 Gábor M KovácsDepartment of Plant Anatomy, Eötvös Lorand University, H-1117 Budapest, Hungary.
Attila BodaDepartment of Anatomy, Cell and Developmental Biology, Eötvös Lorand University, H-1117 Budapest, Hungary.ORCID 0000-0003-1811-8595 Zsolt FarkasDepartment of Biological Anthropology, Eötvös Lorand University, H-1117 Budapest, Hungary.
Krisztina Takács-VellaiDepartment of Biological Anthropology, Eötvös Lorand University, H-1117 Budapest, Hungary.ORCID 0000-0002-4472-0363 Funding
Hungarian Academy of Sciences PC-II-12/2022National Research, Development and Innovation Office FK142971National Research, Development and Innovation Office K134285National Research, Development and Innovation Office PD142943National Research, Development and Innovation Office RRF-2.3.1-21-2022-00015
6 · The paper itselfAbstract
Pheochromocytomas and paragangliomas (PPGL) are classified as rare cancers but can be highly metastatic, particularly in individuals with inherited succinate dehydrogenase B (SDHB) mutations. As current therapies and the availability of
Indexed as
Adrenal Gland NeoplasmsCaenorhabditis elegansCaenorhabditis elegans ProteinsParagangliomaPheochromocytomaSuccinate DehydrogenaseAnimalsAnimals, Genetically ModifiedDisease Models, AnimalHumansMitochondriaMitophagyMutation, MissenseReactive Oxygen SpeciesUbiquitin-Protein LigasesCaenorhabditis elegans ProteinsReactive Oxygen SpeciesSDHB protein, humanSuccinate DehydrogenaseUbiquitin-Protein Ligasesdopaminergic neuronal damagefluopyramfungicidehypoxiamitophagyROSSDHBSDH inhibitorsuccinate dehydrogenase B
Identifiers
PMID41155475
PMCPMC12563477
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390